Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q07075
UPID:
AMPE_HUMAN
Alternative names:
Aminopeptidase A; Differentiation antigen gp160
Alternative UPACC:
Q07075; Q504U2
Background:
Glutamyl aminopeptidase, also known as Aminopeptidase A and Differentiation antigen gp160, plays a pivotal role in blood pressure regulation. It specifically targets and cleaves N-terminal acidic residues from peptides, notably angiotensin II, a key player in the renin-angiotensin system that regulates blood pressure and fluid balance.
Therapeutic significance:
Understanding the role of Glutamyl aminopeptidase could open doors to potential therapeutic strategies. Its unique ability to modulate angiotensin II levels positions it as a promising target for the development of novel antihypertensive treatments.